Sam Boughedda

Decision by the U.S. Food and Drug Administration (FDA). Novavax CNBC reports that the Covid-19 vaccine may be delayed in India’s (NASDAQ)

CNBC received a statement from the FDA stating that any modifications to the manufacturing process of the drugmaker will be examined by the FDA before approval can be granted for the Covid-19 vaccination in the United States.

A committee made up of FDA experts and independent vaccine specialists voted on Tuesday in favor of Novavax’s use in the United States. This was after a thorough review of data regarding safety and effectiveness.

Novavax has already been approved for use in Europe and Britain.

While other vaccines were approved fairly quickly by FDA, Novavax may take longer to be approved. The FDA reportedly told CNBC that Novavax informed them of manufacturing process changes on June 3, only a few days before reviewing its vaccine’s safety and effectiveness.

CNBC’s spokesperson for FDA said that CNBC had quoted CNBC saying the FDA would “carefully examine this information and any other submitted data.”